Du är här


ThromboGenics NV: Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4%

Regulated Information -
Transparency Statement

Leuven, Belgium, 10 September 2015 - Pursuant to Belgian transparency
legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR)
received a transparency notification on 9 September 2015 from Philippe
Vlerick and controlled entities.

Philippe Vlerick (Bareldam SA) notified that on 9 September 2015, 2,324,719
shares, representing 6.44% of the current 36,094,349 outstanding
ThromboGenics shares, were held by himself and controlled entities.

On September 9, 2015, based on all received transparency declarations
received, ThromboGenics NV is aware of the following participations:

| Shareholder number of securities % of voting rights |
| Mr Landon T. Clay and all entities controlled by him 1,071,061 2.97% |
| Mr Thomas M. Clay and all entities controlled by him 2,790,062 7.73% |
| Norges Bank 1,065,605 2.95% |
| Philippe Vlerick and all entities controlled by him 2,324,719 6.44% |
In May, Baron Philippe Vlerick was appointed as a non-executive member of the
Board of ThromboGenics NV at an extraordinary shareholders' assembly that
took place on August 20th.

Philippe Vlerick is the owner, Chairman and CEO of several businesses in
Belgium and abroad. He currently serves as the Chairman and Chief Executive
Officer of Vlerick Group (Belgium). He also serves as the Chairman and CEO of
UCO Textiles NV. In addition, he is the Vice-chairman of KBC Group, Corelio,
smartphoto Group and Durabilis. Baron Vlerick is also a member of the Board
of Directors of Exmar, Hamon&Cie, Besix Group and I.V.C. (Belgium).

Mr Vlerick holds a Degree in Philosophy and Law from the University of Leuven,
and an MBA General Management degree (PUB) (Ghent, Vlerick School of
Management - 1979). He also holds a Master's degree in Business
Administration from Indiana University, Bloomington (USA - 1980).

He was elected 2006 Manager of the Year by Trends, a leading business magazine
in Belgium. He was granted the title of Baron in 2008, and became Commander
of the Order of Leopold in 2013.


For further information please contact:

| ThromboGenics Citigate Dewe Rogerson |
| |
| |
| |
| |
|Wouter Piepers, David Dible/Malcolm Robertson |
| |
|Global Head of Corporate Communications&IR Tel: +44 20 7282 2867 |
| |
|+32 16 75 13 10 / +32 478 33 56 32 Malcolm.robertson@citigatedr.co.uk |
| |
|wouter.piepers@thrombogenics.com |
About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative treatments for diabetic eye disease.

The Company's first product, JETREA®(ocriplasmin), has been approved in 53
countries across the globe. In the US, ThromboGenics is commercializing
JETREA®via its subsidiary ThromboGenics inc. ThromboGenics signed an
agreement with Alcon, a division of Novartis, for the commercialization of
JETREA®outside the United States.

ThromboGenics is planning a Phase II clinical trial with JETREA®in diabetic
retinopathy. Next to JETREA®, the company is in the midst of evaluating a
number of potential candidates for next generation treatments in diabetic eye

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties.
The Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks
and uncertainties affecting the business and other factors that could cause
actual results to differ materially from any forward-looking statement is
contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ThromboGenics NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.